It’s only fair to share… Lomedeucitinib CAS 2328068-29-5 MF C18H172H3N6O4S MW 419.5 g/mol 4-{[3-(methanesulfonyl)pyridin-2-yl]amino}-N-(2H3)methyl-6-[(1R)-spiro[2.2]pentane-1-carboxamido]pyridazine-3-carboxamide 4-[(3-methylsulfonyl-2-pyridinyl)amino]-6-[[(2R)-spiro[2.2]pentane-2-carbonyl]amino]-N-(trideuteriomethyl)pyridazine-3-carboxamideJanus kinase inhibitor, anti-inflammatory, BMS-986322, BMS 986322, EYQ7KA55XA Lomedeucitinib is an investigational new drug that is being evaluated for the treatment of psoriasis and psoriatic arthritis. It is a tyrosine kinase 2 (TYK2) inhibitor.[1] SYN US20210253554 https://patentscope.wipo.int/search/en/detail.jsf?docId=US333829535&_cid=P10-MHIXWK-98212-1 General Scheme for Examples 252 and 253: Example 252 Step 1 A mixture …
Category «Uncategorized»
Lirodegimod
It’s only fair to share… Lirodegimod CAS 2502186-79-8 MF C60H74ClN10O14PS, MW 1257.79 [2-[[(5S,8S,10aR)-3-acetyl-8-[[(2S)-5-amino-1-[2-chloro-3-[4-[[(2S)-1-[(2S,4R)-4-hydroxy-2-[[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]amino]-4-oxobutyl]phenoxy]-5-oxopentan-2-yl]carbamoyl]-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocin-5-yl]carbamoyl]-1H-indole-5-carbonyl]phosphonic acid L-Prolinamide, N-[4-[3-[[(2S)-2-[[[(5S,8S,10aR)-3-acetyldecahydro-5-[[[5-(phosphonocarbonyl)-1H-indol-2-yl]carbonyl]amino]pyrrolo[1,2-a][1,5]diazocin-8-yl]carbonyl]amino]-5-amino-5-oxopentyl]oxy]-2-chlorophenyl]-1-oxobutyl]-3-methyl-L-valyl-4-hydroxy-N-[(1S)-1-[4-(4-methyl-5-thiazolyl)phenyl]ethyl]-, (4R)- KT 333, KT333, ANTINEOPLASTIC, Fast Track (United States), Orphan Drug (United States), 4Q6ZHJ2MNALirodegimod is a small molecule drug. The usage of the INN stem ‘-imod’ in the name indicates that Lirodegimod is a immunomodulator, both stimulant/suppressive and stimulant. Lirodegimod …
Linustedastat
It’s only fair to share… Linustedastat CAS 2254299-48-2 MFC26H29F2N3O2 MW 453.5 g/mol FOR-6219, OG-6219, FOR 6219, OG 6219, PP3PLL7GZY, Phase 2, Endometriosis 3-[(8R,9S,13S,14S,15R,17E)-4-fluoro-17-hydroxyimino-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-15-yl]-N-(5-fluoro-2-pyridinyl)propanamide 3-[(17E)-4-fluoro-17-(hidroxiimino)estra-1,3,5(10)-trien-15β-il]-N-(5-fluoropiridin-2-il)propanamidainhibidor de la hidroxiesteroide 17-beta deshidrogenasa 1(HSD17B1) Linustedastat (developmental code names FOR-6219 and OG-6219) is a 17β-hydroxysteroid dehydrogenase 1 (17β-HSD1; HSD17B1) inhibitor which is under development for the treatment of endometriosis.[1][2][3][4][5] It is a steroidal compound derived from estrone and works by preventing the formation of the more potent estrogen estradiol from …
Iodofalan (131I)
It’s only fair to share… Iodofalan (131I) CAS 76641-05-9 MFC9H10131INO2 Molecular FormulaC9H10INO2 Molecular Weight295.09 4-(131I)iodo-L-phenylalanine (2S)-2-amino-3-(4-iodophenyl)propanoic acidradiopharmaceutical, antineoplastic, Phase 2, Glioblastoma, 606VTF676Y, 131I-TLX-101, ACD 101 Iodofalan (131I) is a radiopharmaceutical that has garnered significant attention in oncological research due to its targeted therapeutic potential. This compound, which includes the radioactive isotope Iodine-131, has been explored …
Inlexisertib
It’s only fair to share… Inlexisertib CAS 2543673-19-2 MF C26H36F3N7O2, 535.62 4-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one 4-[3-[[2-[2-ethyl-4-(4-methylpiperazin-1-yl)anilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]propyl]-1,4-oxazepan-5-one serine/ threonine kinase inhibitor, antineoplastic, DCC 3116, JM2ZTM8S7S Inlexisertib is an orally bioavailable inhibitor of the serine/threonine-protein kinase ULK 1 and 2, with potential antineoplastic activity. Upon oral administration, inlexisertib targets and binds to ULK1/2. This inhibits cancer autophagy, which mutant RAS cancer …
Imocitrelvir
It’s only fair to share… Imocitrelvir CAS 343565-99-1 MFC26H29N5O7 MW523.5 g/mol ethyl (2E,4S)-4-{(2S)-2-[3-(5-methyl-1,2-oxazole-3-carboxamido)-2-oxopyridin-1(2H)-yl]pent-4-ynamido}-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate ethyl (E,4S)-4-[[(2S)-2-[3-[(5-methyl-1,2-oxazole-3-carbonyl)amino]-2-oxo-1-pyridinyl]pent-4-ynoyl]amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoateprotease inhibitor, antiviral, AG-7404, V-7404, AG 7404, V 7404, VQ1AN3OO42 Imocitrelvir is an investigational new drug that is being evaluated for the treatment of viral infections. It is a 3C protease inhibitor in picornaviruses. Originally developed by Pfizer for treating human rhinovirus infections,[1] this small molecule has shown promise against a broader range …
Ilantimod
It’s only fair to share… Ilantimod CAS 2242464-44-2 MF C18H18ClN5O3 MW 387.82 6-(4-chlorophenyl)-N-[(2S)-1-hydroxypropan-2-yl]-2-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydropyridazine-4-carboxamide (S)-6-(4-chlorophenyl)-N-(1-hydroxypropan-2-yl)-2-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydropyridazine-4-carboxamideimmunomodulator, BAY-2416964, BAY 2416964, Y87V4WXQ4Z Ilantimod is an orally available formulation containing a small molecule antagonist of the aryl hydrocarbon receptor (AhR; class E basic helix-loop-helix protein 76; bHLHe76) with potential immunomodulating and antineoplastic activities. Upon oral administration, ilantimod specifically binds to …
Icovamenib
It’s only fair to share… Icovamenib CAS 2448172-22-1 MF C31H34N8O3 MW 566.7 g/mol N-{4-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl}-4-{[(3R)-3-(prop-2-enamido) piperidin-1-yl]methyl}pyridine-2-carboxamide N-[4-(4-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl]-4-[[(3R)-3-(prop-2-enoylamino)piperidin-1-yl]methyl]pyridine-2-carboxamidemenin-MLL (mixed-lineage leukemia) protein interaction inhibitor,antineoplastic, BMF-219, BMF 219, 2Z737MY35A, Menin-MLL inhibitor 21 Icovamenib is an investigational irreversible covalent inhibitor of menin. It is developed by Biomea Fusion for diabetes, lymphoma, leukemia, and multiple myeloma.[1][2][3]Icovamenib is an orally bioavailable, irriversible inhibitor of menin, an essential co-factor of oncogenic …
Ibrilatazar
It’s only fair to share… Ibrilatazar CAS 57818-44-7 MF C18H32O3 MW 296.4 g/mol rac-(2R)-(9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acidperoxisome proliferator activated receptor (PPAR) alpha and gamma agonist, antineoplastic, ABILITY PHARMA, ABTL 0812, alpha-Hydroxylinoleic acid, ABTL0812 Ingredient UNII CAS InChI Key ABTL-0812 Sodium X1840C8161 Not Available VFXKYDDSDQXKLC-NBTZWHCOSA-M Ibrilatazar also known as α-hydroxylinoleic acid is a small-molecule, experimental cancer drug being developed by Ability Pharmaceuticals.[1] …
Glovadalen
It’s only fair to share… Glovadalen CAS 2576359-31-2 MF C24H27Cl2N3O3 MW 476.4 g/mol 2-(3,5-dichloro-1-methyl-1H-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(2-hydroxypropan-2-yl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl]ethan-1-one, 2-(3,5-dichloro-1-methylindazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(2-hydroxypropan-2-yl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanonedopamine D1 receptor positive allosteric modulator, Phase 2, Parkinson’s disease, UCB-0022, UCB 0022, H8T5VKH4CZ Glovadalen (developmental code name UCB-0022) is a dopamine D1 receptor positive allosteric modulator which is under development for the treatment of Parkinson’s disease.[1][2][3][4][5][6] It has been found to potentiate the capacity of dopamine to activate the D1 receptor …